Annals of Hematology

, Volume 95, Issue 5, pp 801–808 | Cite as

Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma

  • Ji Hyun Park
  • Dok Hyun Yoon
  • Shin Kim
  • Jung Sun Park
  • Chan-sik Park
  • Heungsup Sung
  • Sang-Wook Lee
  • Jooryung Huh
  • Cheolwon Suh
Original Article

Abstract

Epstein-Barr virus (EBV) in the peripheral blood has become a significant predictor of clinical outcomes in EBV-associated Hodgkin lymphoma (HL). However, due to its relative rarity, prevalence and prognostic role of circulating EBV-DNA has not been well established in Asian patients. Seventy patients with newly diagnosed HL were prospectively registered between October 2007 and January 2013, and underwent pretreatment whole blood (WB) EBV-DNA quantitation using real-time polymerase chain reaction (RT-PCR). WB EBV-DNA in baseline and serial RT-PCR within 1 year were investigated. Clinicopathologic parameters of the patients according to pretreatment WB EBV-DNA were also explored. Twelve patients (17.1 %) demonstrated WB EBV-DNA(+), which was significantly associated to older age, advanced stages, frequent involvements of extranodal sites, low serum albumin and hemoglobin levels, and high international prognostic scores ≥2. Three-year event-free survival (EFS) and overall survival (OS) were significantly inferior in patients with pretreatment WB EBV-DNA(+) (53.5 vs 67.0 and 65.6 vs 90.2 %) (p < 0.032 and <0.01). Negatively conversed EBV-DNA within 1 year after chemotherapy also significantly affected favorable EFS (p < 0.01). Taken together, pretreatment WB EBV-DNA(+) may be a significant predictor of inferior EFS and OS over EBV-encoded RNA in situ hybridization (EBER-ISH)(+) in Korean patients with HL. Serial EBV-DNA monitoring following chemotherapy also seems helpful to predict survival outcomes.

Keywords

EBV Hodgkin disease Whole blood DNA Prognosis 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

277_2016_2610_MOESM1_ESM.docx (18 kb)
Supplementary Table 1 (DOCX 17 kb)

References

  1. 1.
    Baan R, Grosse Y, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V (2009) A review of human carcinogens—part F: chemical agents and related occupations. Lancet Oncol 10(12):1143–1144CrossRefPubMedGoogle Scholar
  2. 2.
    Fafi-Kremer S, Brengel-Pesce K, Bargues G, Bourgeat MJ, Genoulaz O, Seigneurin JM, Morand P (2004) Assessment of automated DNA extraction coupled with real-time PCR for measuring Epstein-Barr virus load in whole blood, peripheral mononuclear cells and plasma. J Clin Virol 30(2):157–164CrossRefPubMedGoogle Scholar
  3. 3.
    Gandhi MK, Lambley E, Burrows J, Dua U, Elliott S, Shaw PJ, Prince HM, Wolf M, Clarke K, Underhill C, Mills T, Mollee P, Gill D, Marlton P, Seymour JF, Khanna R (2006) Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin’s lymphoma. Clin Cancer Res 12(2):460–464CrossRefPubMedGoogle Scholar
  4. 4.
    Hohaus S, Santangelo R, Giachelia M, Vannata B, Massini G, Cuccaro A, Martini M, Cesarini V, Cenci T, D’Alo F, Voso MT, Fadda G, Leone G, Larocca LM (2011) The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res 17(9):2885–2892CrossRefPubMedGoogle Scholar
  5. 5.
    Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, Kahl BS, Horning SJ, Ambinder RF (2013) Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood 121(18):3547–3553CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lit LC, Chan KC, Leung SF, Lei KI, Chan LY, Chow KC, Chan AT, Lo YM (2004) Distribution of cell-free and cell-associated Epstein-Barr virus (EBV) DNA in the blood of patients with nasopharyngeal carcinoma and EBV-associated lymphoma. Clin Chem 50(10):1842–1845CrossRefPubMedGoogle Scholar
  7. 7.
    Jarrett RF (2003) Risk factors for Hodgkin’s lymphoma by EBV status and significance of detection of EBV genomes in serum of patients with EBV-associated Hodgkin’s lymphoma. Leuk Lymphoma 44(Suppl 3):S27–S32CrossRefPubMedGoogle Scholar
  8. 8.
    Jo SA, Hwang SH, Kim SY, Shin HJ, Chung JS, Sol MY, Chang CL, Lee EY (2010) Quantitation of whole blood Epstein-Barr virus DNA is useful for assessing treatment response in patients with non-Hodgkin’s lymphoma. Int J Lab Hematol 32(1 Pt 1):e106–e113CrossRefPubMedGoogle Scholar
  9. 9.
    Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117(19):5019–5032CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Rappaport H, Berard CW, Butler JJ, Dorfman RF, Lukes RJ, Thomas LB (1971) Report of the committee on histopathological criteria contributing to staging of Hodgkin’s disease. Cancer Res 31(11):1864–1865PubMedGoogle Scholar
  11. 11.
    Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med 339(21):1506–1514CrossRefPubMedGoogle Scholar
  12. 12.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586CrossRefPubMedGoogle Scholar
  13. 13.
    Spacek M, Hubacek P, Markova J, Zajac M, Vernerova Z, Kamaradova K, Stuchly J, Kozak T (2011) Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients. APMIS 119(1):10–16. doi: 10.1111/j.1600-0463.2010.02685.x CrossRefPubMedGoogle Scholar
  14. 14.
    Kimura H, Ito Y, Suzuki R, Nishiyama Y (2008) Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Rev Med Virol 18(5):305–319. doi: 10.1002/rmv.582 CrossRefPubMedGoogle Scholar
  15. 15.
    Kornacker M, Jox A, Vockerodt M, Tesch H, Bohlen H, Diehl V, Wolf J (1999) Detection of a Hodgkin/Reed-Sternberg cell specific immunoglobulin gene rearrangement in the serum DNA of a patient with Hodgkin’s disease. Br J Haematol 106(2):528–531CrossRefPubMedGoogle Scholar
  16. 16.
    Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM (2000) Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol 111(1):239–246CrossRefPubMedGoogle Scholar
  17. 17.
    Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY, Chow KC, Lo YM (2003) Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 63(9):2028–2032PubMedGoogle Scholar
  18. 18.
    Torres Espindola LM, Arellano Galindo J, Velazquez Cruz R, Castillejos Lopez MJ (2013) Factors involved in host-pathogen interaction for the risk of Hodgkin lymphoma induced by Epstein Barr virus. Investig Clin 54(3):311–324Google Scholar
  19. 19.
    Meyer RM (2013) EBV DNA: a Hodgkin lymphoma biomarker? Blood 121(18):3541–3542CrossRefPubMedGoogle Scholar
  20. 20.
    Gartner B, Preiksaitis JK (2010) EBV viral load detection in clinical virology. J Clin Virol 48(2):82–90CrossRefPubMedGoogle Scholar
  21. 21.
    Kapatai G, Murray P (2007) Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol 60(12):1342–1349CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Jones K, Gandhi MK (2010) Can a blood test monitor lymphoma? Leuk Lymphoma 51(6):957–959. doi: 10.3109/10428194.2010.487623 CrossRefPubMedGoogle Scholar
  23. 23.
    Ouedraogo DE, Bollore K, Viljoen J, Foulongne V, Reynes J, Cartron G, Vendrell JP, Van de Perre P, Tuaillon E (2014) Comparison of EBV DNA viral load in whole blood, plasma, B-cells and B-cell culture supernatant. J Med Virol 86(5):851–856CrossRefPubMedGoogle Scholar
  24. 24.
    Kamper PM, Kjeldsen E, Clausen N, Bendix K, Hamilton-Dutoit S, d’Amore F (2005) Epstein-Barr virus-associated familial Hodgkin lymphoma: paediatric onset in three of five siblings. Br J Haematol 129(5):615–617CrossRefPubMedGoogle Scholar
  25. 25.
    Spacek M, Hubacek P, Markova J, Zajac M, Vernerova Z, Kozak T (2010) Can we use EBV-DNA monitoring to predict disease relapse in EBV-positive Hodgkin lymphoma patients? Acta Haematol 124(1):23–26CrossRefPubMedGoogle Scholar
  26. 26.
    Machado AS, Da Silva Robaina MC, Magalhaes De Rezende LM, Apa AG, Amoedo ND, Bacchi CE, Klumb CE (2010) Circulating cell-free and Epstein-Barr virus DNA in pediatric B-non-Hodgkin lymphomas. Leuk Lymphoma 51(6):1020–1027. doi: 10.3109/10428191003746331 CrossRefPubMedGoogle Scholar
  27. 27.
    Ambinder RF, Browning PJ, Lorenzana I, Leventhal BG, Cosenza H, Mann RB, MacMahon EM, Medina R, Cardona V, Grufferman S (1993) Epstein-Barr virus and childhood Hodgkin’s disease in Honduras and the United States. Blood 81(2):462–467PubMedGoogle Scholar
  28. 28.
    Glaser SL, Lin RJ, Stewart SL, Ambinder RF, Jarrett RF, Brousset P, Pallesen G, Gulley ML, Khan G, O’Grady J, Hummel M, Preciado MV, Knecht H, Chan JK, Claviez A (1997) Epstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international data. Int J Cancer 70(4):375–382CrossRefPubMedGoogle Scholar
  29. 29.
    Jarrett RF, Stark GL, White J, Angus B, Alexander FE, Krajewski AS, Freeland J, Taylor GM, Taylor PR (2005) Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood 106(7):2444–2451CrossRefPubMedGoogle Scholar
  30. 30.
    Koh YW, Yoon DH, Suh C, Huh J (2012) Impact of the Epstein-Barr virus positivity on Hodgkin’s lymphoma in a large cohort from a single institute in Korea. Ann Hematol 91(9):1403–1412. doi: 10.1007/s00277-012-1464-8 CrossRefPubMedGoogle Scholar
  31. 31.
    Flavell KJ, Billingham LJ, Biddulph JP, Gray L, Flavell JR, Constandinou CM, Young LS, Murray PG (2003) The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced Hodgkin’s disease. Ann Oncol 14(2):282–290CrossRefPubMedGoogle Scholar
  32. 32.
    Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS (1991) Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s disease. Lancet 337(8737):320–322CrossRefPubMedGoogle Scholar
  33. 33.
    Koh YW, Kang HJ, Yoon DH, Suh C, Kim JE, Kim CW, Huh J (2013) Changing trend of Epstein-Barr virus association in Hodgkin lymphoma in the Republic of Korea. Ann Hematol 92(12):1653–1660. doi: 10.1007/s00277-013-1837-7 CrossRefPubMedGoogle Scholar
  34. 34.
    Keegan TH, Glaser SL, Clarke CA, Gulley ML, Craig FE, Digiuseppe JA, Dorfman RF, Mann RB, Ambinder RF (2005) Epstein-Barr virus as a marker of survival after Hodgkin’s lymphoma: a population-based study. J Clin Oncol 23(30):7604–7613CrossRefPubMedGoogle Scholar
  35. 35.
    Kwon JM, Park YH, Kang JH, Kim K, Ko YH, Ryoo BY, Lee SS, Lee SI, Koo HH, Kim WS (2006) The effect of Epstein-Barr virus status on clinical outcome in Hodgkin’s lymphoma. Ann Hematol 85(7):463–468CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Ji Hyun Park
    • 1
  • Dok Hyun Yoon
    • 1
  • Shin Kim
    • 1
  • Jung Sun Park
    • 1
  • Chan-sik Park
    • 2
  • Heungsup Sung
    • 3
  • Sang-Wook Lee
    • 4
  • Jooryung Huh
    • 2
  • Cheolwon Suh
    • 1
  1. 1.Department of Oncology, Asan Medical Center, College of MedicineUniversity of UlsanSeoulSouth Korea
  2. 2.Department of Pathology, Asan Medical Center, College of MedicineUniversity of UlsanSeoulSouth Korea
  3. 3.Department of Laboratory Medicine, Asan Medical Center, College of MedicineUniversity of UlsanSeoulSouth Korea
  4. 4.Department of Radiation Oncology, Asan Medical Center, College of MedicineUniversity of UlsanSeoulSouth Korea

Personalised recommendations